why choose us

First received: December 07, 2022

Clinical Trial: A Phase 1 Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3

Study Status: Completed

Recruit Status: RECRUITING

Condition: Small Cell Lung Cancer (SCLC)

Study Type: INTERVENTIONAL


Official Title: A Phase 1 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of PT217 in Patients With Advanced Refractory Cancers Expressing DLL3

Brief Summary: PT217 is a bispecific antibody (bsAb) against human DLL3 (huDLL3) and human CD47 (huCD47).This is an open label, Phase I study to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary efficacy of PT217 in subjects with advanced or refractory cancers.Patients with the following tumor types will be eligible for screening: unresectable or small cell lung cancer (SCLC), large cell neuroendocrine cancer (LCNEC), neuroendocrine prostate cancer (NEPC) and gastroenteropancreatic neuroendocrine tumors…

Read more